《生命科学》 2020, 32(1): 83-91

溶瘤病毒疗法在胰腺癌治疗中的研究进展

刘惠玲，黄承浩*

(厦门大学国家传染病诊断试剂与疫苗工程技术研究中心，厦门 361102)

摘　要：摘　要：胰腺癌是恶性程度最高的消化道肿瘤之一，极难治疗，患者五年生存率不足15%。在过去20年中，有许多溶瘤病毒被尝试用于治疗胰腺癌，其中有一部分已经步入临床试验阶段。由于溶瘤病毒疗法毒副作用较低，且可与免疫治疗、靶向治疗等方法有机结合，对于需要长期维持治疗以及单一疗法疗效较差的胰腺癌而言无疑是很好的选择。该文主要介绍了几种溶瘤病毒的基因改造方法、作用原理以及临床前实验结果，并对溶瘤病毒疗法治疗胰腺癌存在的挑战和相应解决办法进行讨论。

Progress in oncolytic virotherapy for the treatment of pancreatic cancer

LIU Hui-Ling， HUANG Cheng-Hao*

(National Institute of Diagnostics and Vaccine Development in Infectious Diseases，
    Xiamen University， Xiamen 361102， China)

Abstract: Abstract: Pancreatic cancer， one of the most malignant tumors of the digestive tract， is extremely difficult to treat and the five-year survival rate is less than 15%. In the past two decades， many oncolytic viruses have been used to treat pancreatic cancer， and some of them have entered clinical trials. Oncolytic virus therapy， which is available to combine with immunotherapy or targeted therapy and has low side effects， is a good choice of pancreatic cancer that requires long-term maintenance therapy and has poor efficacy of monotherapy. This article mainly introduces the genetic modification methods， principle of action and preclinical experimental results of several oncolytic viruses， and discusses the challenges and corresponding solutions to the treatment of pancreatic cancer by oncolytic virus therapy.